Insider buying last 90 days
No open-market insider purchases were filed for PGEN in the last 90 days.
From Form 4 filings, dated to when each was filed.
Every PGEN insider filing, plotted on the chart in Gekko.Open PGEN in Gekko
NASDAQ: PGEN
Precigen (PGEN) Stock Analysis & Forecast
Oct 12 close
$7.66−0.15 (−1.9%)
Gekko Brief
AI summaryOct 12 closePrecigen's stock continues to build on momentum tied to Papzimeos sales growth, a European regulatory review and progress across its AdenoVerse pipeline, with coverage this week noting the stock is up more than 50% over three months. Comparative analyses against peers such as Pyxis Oncology and PTC Therapeutics also circulated, weighing Precigen's analyst recommendations, valuation and earnings profile against those companies without new company-specific disclosures.
PGEN closed at $7.66, down 1.9% on the day, but remains above both its 50-day average of $7.27 and its 200-day average of $5.11, with the 50-day above the 200-day. The GekkoIndex reads 57, placing the stock in the Neutral zone. Shares trade 21% below the Gekko Fair Value of $9.70, a gap that has persisted even as the stock has advanced 11.8% over one month and 140.1% over the past year.
The next earnings report is scheduled for 12 November 2026 after the close, 31 days away and outside a typical 20-trading-day holding window; the prior quarter saw an EPS beat and a 4.2% reaction. No insider, Congress or unusual options activity appears in the current windows. Seasonality data show the next 20 trading days have averaged a 7.7% gain over five years, rising in four of them, a pattern worth noting alongside the stock's typical 20-day move of 14%.
Written by AI from the Oct 12, 2026 close and checked automatically against the figures on this page.
Precigen price vs fair value
Close $7.66200-day averageGekko Fair Value $9.70
Precigen quick facts
- Market cap
- $2.73B
- P/E ratio
- —
- Forward P/E
- 16.9
- EPS, TTM
- −$1.04
- Revenue, TTM
- $85.72M
- Profit margin
- -184%
- Dividend yield
- —
- Beta
- 0.92
- Volume
- 2.16M avg 5.65M
- 1-year return
- +140.1%
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±14%
- 50-day average
- $7.27
- 200-day average
- $5.11
- Next earnings
- Nov 12 after close
- Shares outstanding
- 358.0M
Precigen swing-trade checklist
Precigen scores 4 supportive, 1 mixed and 0 headwinds across the 5 checklist items with data.
Six things swing traders check before a 20-day hold, read from the latest data.
4 supportive1 mixed0 headwinds
- Trendsupportive
Above 50 and 200-day
Close $7.66 is above the 50-day ($7.27) and 200-day ($5.11) averages, and the 50-day is above the 200-day.
See the chart - GekkoIndexmixed
57, Neutral
Reading 57 is in the Neutral zone.
See the GekkoIndex - Fair valuesupportive
21.0% below
Price is 21% below Gekko Fair Value (more than 5% below).
See fair value - Smart moneyno data
No data
No insider, Congress or unusual options activity in the window.
See smart money - Earnings risksupportive
Reports in 31 days
Next report Nov 12, 2026, 31 days away — outside a typical 20-trading-day hold.
See earnings - Seasonalitysupportive
+7.7% on average
From this point in the calendar, the next 20 trading days averaged +7.7% over 5 years, rising in 4 of them.
See seasonality
A description of current data, not a recommendation. How this page works
Precigen stock chart and price history
Precigen closed at $7.66 on Oct 12, 2026, +140.1% over the past year, inside a 52-week range of $2.99 to $8.98.
Close50-day average200-day averageVolume
Use the left and right arrow keys to read daily values.
Performance Breakdown
- 1 month
- +11.8%
- 3 months
- +49.6%
- 6 months
- +83.7%
- 1 year
- +140.1%
The full PGEN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open PGEN in Gekko
Follow Precigen through every session
Put PGEN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.
Track PGEN in GekkoFree for 7 days. No credit card required.
About Precigen
Precigen works on gene and cell therapies, aiming to treat disease at its genetic roots. Alongside these therapeutic efforts, it has worked with genetically engineered swine for regenerative medicine and with reproductive and embryo transfer methods. Its work rests on a set of proprietary technologies, including tools for building and controlling gene expression, a non-viral system for modifying genetic material, precision DNA recombination tools, engineered viral vectors for gene delivery, switches that regulate or shut down therapeutic activity in the body, and a platform aimed at cancer treatment through modified immune cells.
The company pairs its own research with partnerships, holding collaboration and licensing arrangements with other firms such as Alaunos Therapeutics, Ares Trading, Oragenics, Castle Creek Biosciences, and the Intrexon Energy Partners entities. These relationships extend the reach of its platforms into additional therapeutic and applied uses beyond what Precigen develops on its own.
The company traces its origins to 1998 under the name Intrexon Corporation, taking on the Precigen name in January 2020. It is headquartered in Germantown, Maryland, and its shares are listed on the NASDAQ under the ticker PGEN.
- Listed
- NASDAQ
- Sector
- Health technology
- Industry
- Biotechnology
- Website
- precigen.com
Precigen GekkoIndex: the smart money zone
Precigen’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 57, in the Neutral zone, up 4.3 points over five sessions.
57Neutral
Up 4.3 points over five sessions.
Reading for Oct 12, 2026
What followed past readings in each zone
| Zone | Readings | 5 days | 20 days | ||
|---|---|---|---|---|---|
| Buying | 28 | +6.0% | +7.8% | ||
| Accumulation | 189 | +2.4% | +13.1% | ||
| Neutral (current zone) | 407 | +1.7% | +7.9% | ||
| Distribution | 55 | +1.1% | −1.5% | ||
| Selling | 3 | Too few readings yet | |||
Average PGEN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +1.1% over 20 days. Past behaviour doesn’t guarantee future results.
Neutral zone: No clear directional signal. About the five zones →
See every daily GekkoIndex reading plotted over the PGEN price, zone by zone.Track PGEN in Gekko
Is Precigen stock overvalued? Gekko Fair Value
Precigen trades 21.0% below Gekko Fair Value of $9.70, so the shares are undervalued on Gekko’s estimate.
Gekko’s own estimate of what Precigen shares are worth, recalculated every trading day.
$9.70
Gekko Fair Value, Oct 10, 2026
21.0% Undervalued
At the end of Aug 2026 the price was 40.0% below the estimate.
Gekko Fair ValueShare price, month end
Gekko Fair Value on every chart, with the gap to price updating daily.Open PGEN in Gekko
Precigen insider and Congress trading
No open-market insider purchases were filed for Precigen, and no Congress trades were disclosed, in the last 90 days.
Plus buybacks, unusual options and fund positions, each dated to when it became public.
Congress trades last 90 days
No trades in PGEN were disclosed by members of Congress in the last 90 days.
From congressional disclosures, which report amounts as ranges.
Congress disclosures for PGEN, plotted on the chart in Gekko.Open PGEN in Gekko
Buybacks
Precigen has been buying back its own shares.
- Bought back, quarter ended Jun 30, 2026
- $1.50M
- As a share of market cap
- 0.05%
From company filings.
Precigen earnings: next date and track record
Precigen reports on Nov 12, 2026, after the close (31 days away), and beat the EPS estimate in 4 of its last 8 reports.
Next earnings report
Nov 12, 2026
Expected after the close, 31 days away
- EPS estimate
- $0.06
- Revenue estimate
- $72.31M
4 of 8reports beat the EPS estimate
±11.6%average move across the report
6 of 8reports followed by a gain
Share-price move across each report
Last earnings call, Aug 4, 2026 AI summary
- What they said
- Precigen reported Q2 2026 PAPZIMEOS revenue of $53.1 million, up 145% from $21.6 million in Q1 2026, achieving quarterly net profit before the product's first approval anniversary. PAPZIMEOS, the first FDA-approved therapy for adult RRP, holds 7-year market exclusivity until August 2032. Durability data shows 83% of complete responders remain surgery-free beyond 3 years. Management sees expanding physician adoption across major medical centers and community practices.
- Guidance
- Management expressed confidence in durable multi-year growth for PAPZIMEOS, citing broadening patient access and continued physician adoption. The company believes RRP represents blockbuster revenue potential, with Q3 momentum continuing to build across multiple commercial dimensions.
| Reported | EPS | Revenue | Move |
|---|---|---|---|
| Aug 4, 2026 | $0.05 est −$0.02 | $54.98M est $27.98M | +4.2% |
| May 13, 2026 | −$0.02 est −$0.03 | $23.25M est $20.81M | +12.7% |
| Mar 25, 2026 | −$0.07 est −$0.10 | $4.58M est $8.42M | +24.3% |
| Nov 13, 2025 | −$1.06 est −$0.08 | $2.92M est $500K | +20.6% |
| Aug 12, 2025 | −$0.11 est −$0.09 | $878K est $952K | +9.8% |
| May 14, 2025 | −$0.18 est −$0.08 | $1.34M est $650K | −3.0% |
| Mar 19, 2025 | −$0.04 est −$0.06 | $1.19M est $3.03M | +7.8% |
| Nov 14, 2024 | −$0.09 est −$0.09 | $953K est $1.30M | −10.4% |
“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.
Precigen stock forecast and analyst price targets
Analysts’ average 12-month price target for Precigen is $13.65, +78.2% from the last close, from 2 firms rating the stock in the last 90 days.
$13.65consensus 12-month target, +78.2% from the last close
Now $7.66Avg $13.65
Low $12High $18
Each firm’s latest rating in the last 90 days: 2 firms.
Latest analyst actions
| Date | Firm | Target | vs price |
|---|---|---|---|
| Oct 1 | H.C. Wainwright | $18 | +135.0% |
| Sep 25 | B. Riley Securities | $12 | +56.7% |
| Sep 21 | H.C. Wainwright | $18 | +135.0% |
| Aug 3 | H.C. Wainwright | $14 | +82.8% |
+7.9%average 20-day move after past Neutral readings
+7.7%average move over the next 20 trading days in the last 5 years
±6.5%typical daily move, from the 14-day average range
Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.
Precigen seasonality: the next 20 trading days
Over the next 20 trading days from Oct 10, Precigen averaged +7.7% across the last 5 years, rising in 4 of them.
Next 20 trading days, by year
Average move and hit rate
| Window | Average | Years higher |
|---|---|---|
| Next 5 trading days | +7.9% | 4 of 5 |
| Next 10 trading days | +7.8% | 2 of 5 |
| Next 15 trading days | +5.6% | 2 of 5 |
| Next 20 trading days | +7.7% | 4 of 5 |
| Next 30 trading days | +0.4% | 2 of 5 |
For scale, PGEN’s typical 20-trading-day move in either direction is about 14%.
Precigen market cap and key statistics
Precigen’s market cap is $2.73B and revenue of $85.72M over the last twelve months.
Valuation
- Market cap
- $2.73B
- Forward P/E
- 16.9
- EPS, TTM
- −$1.04
- Gekko Fair Value
- $9.70
Trading
- Volume
- 2.16M
- Avg volume, 20 days
- 5.65M
- 52-week high
- $8.98
- 52-week low
- $2.99
- Shares outstanding
- 358.0M
Financials
- Revenue, TTM
- $85.72M
- Profit margin
- -184%
- Return on equity
- -837%
- Quarterly earnings growth, YoY
- 0.0%
Risk and income
- Beta
- 0.92
- Typical daily move
- ±6.5%
- Typical 20-day move
- ±14%
Precigen stock news this week
4 headlines about Precigen from the past week, newest first, each linking to the publisher.
- Pyxis Oncology (NASDAQ:PYXS) & Precigen (NASDAQ:PGEN) Head to Head AnalysisDefense World, Oct 10
- Price to book forward of Precigen Inc – HAM:I5XTradingView, Oct 7
- PGEN Stock Up More Than 50% in 3 Months: Here's What You Should KnowZacks Investment Research, Oct 5
- Comparing PTC Therapeutics (NASDAQ:PTCT) and Precigen (NASDAQ:PGEN)Defense World, Oct 5
Precigen peers
Precigen’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.
| Stock | GekkoIndex zone | vs Fair Value |
|---|---|---|
| AMGNAmgen | Neutral | 25.5% below |
| GILDGilead Sciences | Neutral | 4.2% above |
| MRNAModerna | Neutral | 62.7% above |
| NTRANatera | Neutral | 10.3% above |
| IQVIQVIA | Neutral | 8.4% above |
| UTHRUnited Therapeutics | Neutral | 14.4% below |
A peer links to its own page where one exists.
Precigen stock FAQ
What is Precigen’s market cap?
Precigen’s market cap is $2.73B at the Oct 12, 2026 close of $7.66, with 358.0M shares outstanding.
What is the Precigen stock forecast?
The consensus analyst 12-month price target for Precigen is $13.65, +78.2% from the last close. Of the 2 firms that rated the stock in the last 90 days, 2 rate it a buy, 0 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.
Is Precigen stock overvalued or undervalued?
On Gekko’s estimate Precigen is undervalued: the Oct 12, 2026 close of $7.66 is 21.0% below Gekko Fair Value of $9.70. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.
When does Precigen report earnings next?
Precigen is expected to report on Nov 12, 2026, after the market closes (31 days away). Analysts expect earnings of $0.06 per share on revenue of $72.31M. Precigen beat the earnings estimate in 4 of its last 8 reports, moving 11.6% on average across the report.
What is Precigen’s 52-week high and low?
Precigen’s 52-week high is $8.98 and its 52-week low is $2.99; it closed at $7.66 on Oct 12, 2026, +140.1% over the past year.
Is Precigen stock a buy right now?
Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 4 of the 5 items with data read as supportive (trend, fair value, earnings risk and seasonality), 1 as mixed (gekkoindex). The checklist is a description of current data, not a recommendation.
How this page works
During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →
See Precigen the way Gekko members do
Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.
Join 1,408 other traders using Gekko
Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.